AcquiredStartups
Home/North America/Healthtech & bio
Acquisition · Healthtech & bio · United States

AstraZeneca acquires St. Louis vaccine startup Omniose after three-year research partnership

The drugmaker already had exclusive rights to Omniose's single-cell bioconjugation platform through a 2024 collaboration. Now it owns the company outright and has folded it into its infectious disease unit.

ASAcquired deals deskNorth America10 November 2026 · 3 min read
AstraZeneca acquires Omniose
Photo: Ajay Kumar Chaurasiya / Wikimedia Commons, CC BY-SA 4.0

AstraZeneca has acquired Omniose, a preclinical biotechnology company in St. Louis that develops conjugate vaccines against serious bacterial infections. Omniose announced the deal on November 10, 2026, in a press release distributed by Business Wire.

Financial terms were not disclosed. Omniose said it now operates as a wholly owned subsidiary of AstraZeneca and sits inside the drugmaker's Infectious Disease Unit. AstraZeneca gains Omniose's proprietary bioconjugation platform, which it plans to use in its preclinical vaccine programs.

The purchase follows a three-year exclusive research collaboration between the two companies. Neither side said how many Omniose staff are moving over, which pathogens the work will target first, or when any candidate might reach human trials.

What Omniose built

Conjugate vaccines work by attaching a sugar molecule from the surface of a bacterium, known as a polysaccharide, to a carrier protein, which helps the immune system respond to it. Conventional manufacturing makes the two parts separately and joins them through chemical processing that involves several purification steps.

Omniose's approach does the whole job biologically. Engineered E. coli cells produce the polysaccharide antigen, an engineered carrier protein and an enzyme that links the two, all within the same cell. The company says the method is simpler and more precise than chemical conjugation, can keep the polysaccharide closer to its natural structure, and could lead to better vaccines. It also says the platform can attach virtually any bacterial polysaccharide, widening a range that earlier bioconjugation enzymes had limited.

The name Omniose means "all sugars", according to the company's website, which lists Group B Streptococcus, Klebsiella pneumoniae and Streptococcus pneumoniae among its targets. BioPharm International noted that the acquisition announcement itself gave no clinical, yield or purity data.

“Omniose’s bioconjugation platform represents a differentiated approach to engineering conjugate vaccines and strengthens our ability to develop novel vaccines against serious bacterial infections.”Benjamin Moutier, Senior Vice President, Infectious Disease, AstraZeneca

From partner to owner

The two companies first signed a deal in January 2024. Under that agreement, AstraZeneca received exclusive rights to Omniose's platform for up to three years to research vaccines for bacterial pathogens within its early-stage vaccines pipeline, including multidrug-resistant bacteria often called superbugs. Financial terms of that collaboration were not disclosed either.

With the exclusivity period close to running its course, AstraZeneca has now taken full control of a technology it has worked with for nearly three years. Dealroom described the deal as a conversion of the research partnership into ownership and noted that it is unlikely to add products or revenue soon, since Omniose's programmes are still preclinical.

Benjamin Moutier, AstraZeneca's senior vice president for infectious disease, said the platform offered a different way of engineering conjugate vaccines and would strengthen the company's ability to develop new vaccines against serious bacterial infections. He said AstraZeneca would build on the scientific work the two teams had already done together.

The founders and the funding

Omniose is led by chief executive Timothy Cooke. Christian Harding, its chief scientific officer, is described on the company's website as its primary founder; he left an academic post in 2017 to lead the formation of the company. Harding completed a postdoctoral fellowship at Washington University in St. Louis under Mario Feldman, who is listed as a co-founder along with Christine Szymanski. Feldman and Szymanski had earlier co-founded VaxAlta, a livestock vaccine company, at the University of Alberta.

PharmExec reported that Feldman also contributed to the research that led GSK to industrialise bioconjugate vaccine technology from GlycoVaxyn and LimmaTech.

Omniose has not reported any venture rounds or named investors. Its website says Harding secured eight federal SBIR and STTR grants worth more than $14 million in total, all non-dilutive funding.

Cooke called the sale a good result for both sides and said the companies wanted to bring science and talent together against bacterial infections that are increasingly complicated by antimicrobial resistance.

Big pharma shops for vaccine platforms

Dealroom placed the purchase within a broader pattern of large drugmakers buying early-stage technology platforms to fill their pipelines, rather than waiting for late-stage assets.

The underlying bioconjugation approach has already reached the clinic elsewhere. According to PharmExec, Janssen, now Johnson & Johnson Innovative Medicine, licensed related technology for a vaccine against nine serotypes of extraintestinal pathogenic E. coli that is in Phase III trials, while GSK's work produced a Shigella candidate in Phase IIb and a Klebsiella pneumoniae candidate in Phase I. Whether Omniose's platform delivers similar candidates for AstraZeneca will depend on how its preclinical programmes progress.

Sources